**Poster Session B**

Friday, November 4, 2016
12:30 p.m.–3:00 p.m.
sopranos

**B01 Histone acetyltransferase 1 contributes to colon cancer initiating cell chemoresistance through DNA damage repair pathways.** Lauren Agro, University of Toronto, Toronto, ON, Canada.

**B02 DNA repair landscape in High Grade Ovarian Cancer (HGOC) and evolution with neo-adjuvant chemotherapy.** Aurelie Auguste, Gustave Roussy - INSERM U981, Villejuif, France.

**B03 Expression and clinical role of Chk1 and Chk2 in high-grade serous carcinoma effusions.** Marianne Bjornerem, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.

**B04 A 53BP1 integrates DNA repair and p53-dependent cell fate decisions via distinct mechanisms.** J Ross Chapman, University of Oxford, Oxford, United Kingdom.

**B05 DNA-PK links DNA repair to metabolism and cancer progression in prostate cancer.** Emanuela Dylgjeri, Sidney Kimmel Cancer Center, Philadelphia, PA, United States.

**B06 SIRT2 directs DNA-PKcs in the DNA damage response.** PamelaSara Head, Emory University, Atlanta, GA, United States.

**B07 Learning from human tumors: Modeling of Mre11 complex patient mutations in yeast.** Marcel Hohl, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

**B08 Normal and neoplastic tissues with partial Hus1 impairment show hypersensitivity to cisplatin in vivo.** Kelly Hume, Cornell University, Ithaca, NY, United States.

**B09 DNA damage inducible phosphorylation of ATR at threonine 1989 and quantitative analysis of the effect of ATR inhibition on DNA damage signaling using PTMScan.** Susan Keezer, Cell Signaling Technology, Inc., Danvers, MA, United States.

**B10 The role of Down syndrome’s DYRK1A kinase in repair of the DNA double-strand breaks.** Larisa Litovchick, Virginia Commonwealth University, Richmond, VA, United States.

**B11 Mechanisms of regulation of the tumor suppressor PALB2.** Jean-Yves Masson, Laval University Cancer Research Center, Quebec, QC, Canada.

**B12 Effect of Ganoderma lucidum on DNA damage and DNA repair in colorectal cancer cell lines.** Alena Opattova, Institute of Experimental medicine, AS CR, Prague, Czech Republic.

**B13 Involvement of PAF1 complex in the DNA damage response.** Garin Park, POSTECH, Pohang, Korea, Republic Of.

**B14 A novel role for BRD9 in regulating cellular growth and DNA damage response pathways.** Caroline Vallaster, AstraZeneca, Waltham, MA, United States.

**B15 Dissecting the molecular mechanism of dianhydrogalactitol (VAL-083) activity in cancer treatment.** Beibei Zhai, The University of British Columbia, Vancouver, BC, Canada.
B16 The transcriptional repressor Slug promotes the DNA damage response. Wenhui Zhou, Tufts University School of Medicine, Boston, MA, United States.

B17 Development of novel, potent orally available Wee1 inhibitors with robust antitumor efficacy in vivo. Gerald Gavory, Almac Discovery, Belfast, United Kingdom.


B19 The ATR inhibitor, AZD6738, synergizes with other DNA damage response inhibitors and genotoxic drugs in pancreatic ductal adenocarcinoma cell lines: Opportunities for new therapeutic combinations. Yann Wallez, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom.

B20 Schedule-dependent activation of DNA helicases by Checkpoint Kinase 1 inhibition following dNTP depletion causes CDK2-independent replication catastrophe. Nicholas Warren, Dartmouth College, Hanover, NH, United States.

B21 The selective ATR inhibitor VX-970 enhances the therapeutic effects of standards of care in glioblastoma. Danielle Burgenske, Mayo Clinic, Rochester, MN, United States.

B22 Targeting DNA double-strand break repair to potentiate radio- and chemo-therapy of glioblastoma. Sandeep Burma, University of Texas Southwestern Medical Center, Dallas, TX, United States.


B24 Genomic prediction of response to PARP inhibition in breast cancer. Saima Hassan, l'Université de Montréal, Montreal, QC, Canada.


B26 Development of a proximity ligation assay for the detection of PARP-1 trapped to chromatin. Todd Hopkins, Abbvie, Inc., North Chicago, IL, United States.

B27 Co-inhibition of ATM and TDP1 as a novel chemosensitization strategy against malignant brain tumors. Sachin Katyal, University of Manitoba/CancerCare Manitoba, Winnipeg, MB, Canada.

B29 A pilot image-based high-throughput screen to identify DNA damage agents: From antimicrobial feed to preclinical testing in malignant brain tumors. Yi Chieh Lim, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Poster Session B
Friday, November 4, 2016
12:30 p.m.–3:00 p.m.
Soprano

B30 Talazoparib efficacy is enhanced by noncytotoxic doses of temozolomide-mediated DNA damage in prostate cancer cell lines. Jeffrey Lindquist, Medivation, Inc., San Francisco, CA, United States.


B32 CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index. Scott Eliasof, Cerulean Pharma Inc., Waltham, MA, United States.

B33 PARP-dependent co-modulation of DNA repair and microglial activity as a dual-pronged anti-glioblastoma treatment strategy. Asha Sinha, University of Manitoba, Winnipeg, MB, Canada.

B34 Development of novel small molecule inhibitors targeting DNA repair proteins. John Turchi, NERx Biosciences, Indianapolis, IN, United States.

B35 Targeted inhibition of Rad51 by the cell-penetrating antibody 3E10. Audrey Turchick, Yale University, New Haven, CT, United States.

B36 Targeting BRCA1 through natural HSP90 inhibitors to reverse platinum resistance in TNBC. Kelli Valdez, University of Kansas Medical Center, Kansas City, KS, United States.

B37 PARP inhibitor olaparib induces genomic instability in normal mammalian cells. Fabio Vanoli, Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B38 Radiation enhances intracellular delivery of anti-MGMT oligomers to reduce protein expression in vitro and in a xenograft model. Jeffrey Wu, OHSU, Portland, OR, United States.

B39 Tumor hypoxia induces DNA repair vulnerabilities through contextual “loss-of-heterozygosity”. Osman Mahamud, Princess Margaret Cancer Centre, Toronto, ON, Canada.

B40 [10]-gingerol as a pro-apoptotic molecule in triple-negative breast cancer. Ana Carolina Martin, Federal University of Sao Carlos, Sao Carlos, SP, Brazil.

B41 REV7 is a possible prognostic predictor and a potential therapeutic target in human malignancy. Yoshiki Murakumo, Kitasato University School of Medicine, Sagamihara, Japan.

B42 Ionizing radiation-induced tumorigenesis is associated with exome-wide mutational signatures conserved in mice and humans. Jean Nakamura, University of California, San Francisco, San Francisco, CA, United States.

B43 RECQ1, a breast cancer susceptibility gene, is upregulated by cancer therapeutics in a p53-dependent manner. Sudha Sharma, Howard University College of Medicine, Washington, DC, United States.
B44 Dual targeting of PI3K and MEK impairs DNA double-strand break repair as a relevant mechanism for radioresistance of K-RAS mutated non-small cell lung cancer. Mahmoud Toulany, University of Tuebingen, Tuebingen, Germany.

B45 A genome-scale screen identifies the microcephaly gene, ZNF335, as a regulator of DNA end resection. Jordan Young, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada.

B46 APOBEC activity in cancer cells confers susceptibility to ATR inhibition. Lee Zou, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, MA, United States.